Loading
A phase 3 trial of Pasritamig, Docetaxel and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 3 interventional study registered as NCT07225946 by Janssen Research & Development, LLC, with 800 participants planned, started 2025-12-19 and due to reach its primary completion in 2027-11-19. Interventions recorded: Pasritamig, Docetaxel and Prednisone/Prednisolone.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Prednisone, Docetaxel, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Prednisone, Docetaxel, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/